About aldeyra therapeutics - ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
ALDX At a Glance
Aldeyra Therapeutics, Inc.
131 Hartwell Avenue
Lexington, Massachusetts 02421
| Phone | 1-781-761-4904 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -55,851,444.00 | |
| Sector | Health Technology | Employees | 9 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
ALDX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 4.192 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.524 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.073 |
ALDX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -6,205,716.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ALDX Liquidity
| Current Ratio | 5.476 |
| Quick Ratio | 5.476 |
| Cash Ratio | 5.438 |
ALDX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -44.163 |
| Return on Equity | -58.545 |
| Return on Total Capital | -64.712 |
| Return on Invested Capital | -54.206 |
ALDX Capital Structure
| Total Debt to Total Equity | 21.552 |
| Total Debt to Total Capital | 17.731 |
| Total Debt to Total Assets | 14.629 |
| Long-Term Debt to Equity | 21.125 |
| Long-Term Debt to Total Capital | 17.38 |